Table 3.
Antibiotics | Overall | Patients Living in Nursing Home | Community-Dwelling Patients | |||
---|---|---|---|---|---|---|
Enterobacterales (n = 171) |
Pseudomonas aeruginosa (n = 8) |
Enterobacterales (n = 39) |
Pseudomonas aeruginosa (n = 3) |
Enterobacterales (n = 132) |
Pseudomonas aeruginosa (n = 5) |
|
Susceptibility rate, % | ||||||
Ampicillin | 50 | 0 | 36 | 0 | 55 | 0 |
Ampicillin-sulbactam | 68 | 0 | 59 | 0 | 71 | 0 |
Piperacillin-tazobactam | 99 | 88 | 100 | 100 | 99 | 80 |
Cefazolin | 66 | 0 | 56 | 0 | 69 | 0 |
Cefmetazole | 92 | 0 | 90 | 0 | 93 | 0 |
Ceftriaxone | 81 | 0 | 64 | 0 | 86 | 0 |
Cefepime | 83 | 88 | 69 | 100 | 87 | 80 |
Meropenem | 100 | 63 | 100 | 100 | 100 | 40 |
Aztreonam | 81 | 63 | 67 | 33 | 85 | 80 |
Amikacin | 100 | 100 | 100 | 100 | 100 | 100 |
Levofloxacin | 75 | 88 | 54 | 100 | 81 | 80 |
TMP-SMX | 89 | 0 | 79 | 0 | 92 | 0 |
Minocycline | 87 | 0 | 82 | 0 | 87 | 0 |
Abbreviations: TMP-SMX, trimethoprim-sulfamethoxazole.